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LETTER/REPLIES
Choosing Wisely: Highest Cost Tests in Outpatient
Neurology
Peter A. Grant, MD,1 Francis O. Walker, MD,2
and John C. Kincaid, MD3
We applaud the intent of the recent Annals of Neurology article,
“Choosing Wisely: Highest-Cost Tests in Outpatient Neuro-
logy,”1 in which the authors identified ways to manage health
care costs. However, no data show that high test costs correlate
with unnecessary use, as suggested by the authors. But data do
show that electrodiagnostic (EDX) testing, which they identi-
fied as a global high-cost procedure, can save health care dollars
when other high-cost procedures are not needed based on the
EDX test results.
For example, Fox and colleagues demonstrated the cost
savings of using trained physicians to perform these tests.2 They
studied whether an insurer rule requiring consultation by back
pain specialists, in this case physiatrists, before nonurgent surgi-
cal consultation would affect surgery rates. The results showed a
12.1% decrease in total spine care costs and a 25.1% decrease in
surgical costs overall, representing a net decrease of more than
$14 million in 1 year. EDX testing was 1 tool used to determine
the need for surgery. Research on upper limb complaints shows
that, in 42% of patients undergoing EDX testing by a properly
trained physician, a diagnosis other than those indicated in the
referral is identified.3 An early and accurate diagnosis eliminates
the need for further tests and ensures patients receive appropriate
treatments quickly, thereby reducing health care spending.
In 1997, the American Association of Neuromuscular
and Electrodiagnostic Medicine (AANEM) addressed appropri-
ate use of EDX testing in its Recommended Policy for Electro-
diagnostic Medicine.4 Now the AANEM is developing a top 5
list of diagnoses for which electromyography is not indicated
for the Choosing Wisely campaign.
As AANEM members, we agree that patients need to have
thoughtful conversations with their health care providers on the
necessity of testing. But cost is just 1 variable that needs to be
assessed. The development of national databases and electronic med-
ical record systems has made cost data widely accessible, whereas
researching patient outcomes remains time consuming. In the best
interests of patients, we recommend a balanced approach, weighing
the costs of diagnostic procedures against the benefits identified in
outcomes research. The key to reducing health care spending is to
ensure the right test is performed at the right time by the right pro-
vider—and sometimes the right test is an EDX test.
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Reply
James F. Burke, MD, MS, Lesli E. Skolarus, MD, MS,
Brian C. Callaghan, MD, MS, Kevin A. Kerber, MD, MS
In response to unsustainable growth in health care expenditures
and concerns about unnecessary care, the Choosing Wisely ini-
tiative—which is supported by >50 medical societies—was
started as a proactive effort to reign in unnecessary spending.
Early Choosing Wisely initiatives had a common weakness—
targets were responsible for modest aggregate costs. Conse-
quently, even if spending on these targets were completely
eliminated, there would be little impact on health care growth.
So, although we agree with Grant et al that valuing health care
services requires consideration of both clinical utility and cost,
the explicitly stated purpose of our study was to define the cost
side of the value equation. Our goal was to help initiatives in
neurology to implement Sutton’s law and go “where the money
is” when identifying diagnostic Choosing Wisely targets.
Since our analysis, the American Academy of Neurology
published the first neurology Choosing Wisely targets. The list
includes 2 diagnostic tests, which were both relatively low aggre-
gate cost items: “Do not perform EEG [electroencephalography]
for headache” and “Do not image the carotid arteries for simple
syncope.”1 Use of EEG for headache accounts for about 10% of
the expenditures of neuroimaging for headache. Thus, targeting
even 20% of headache neuroimaging studies would have twice
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the cost-reducing potential of targeting all headache EEGs. Simi-
larly, although Grant et al argue for the value of electromyogra-
phy (EMG) in some clinical contexts, it is less clear what
proportion of the $500 million spent annually by US neurolo-
gists on EMGs is clinically valuable and what proportion may be
unnecessary testing. Thus, we applaud the American Association
of Neuromuscular Electrodiagnostic Medicine’s plan to develop
an EMG-specific set of Choosing Wisely targets and hope that
they systematically consider the cost of their targets.
Data on regional variation in health care expenditures
suggest that 30% of all expenditures may be unnecessary.2
Although these data define an enormous problem, they do not
inform which 30% of health care expenditures is unnecessary.
For neurology, identifying unnecessary care is particularly chal-
lenging, because neurologists heavily rely on costly diagnostic
tests and few data exist for determining the value of tests. Even
for routine tests for common neurologic diseases,3 little is
known about whether these tests change management or
improve patient outcomes.4 Thus, to understand and ultimately
limit unnecessary neurologic care, more research is needed to
determine the value of neurologic diagnostic testing.5 We hope
that our study, by identifying high aggregate cost targets, serves
to establish priority areas for such future investigations.
Potential Conflicts of Interest
Nothing to report.
Department of Neurology, University of Michigan, Ann Arbor,
MI
References
1. Five things patients and physicians should question. Available at:
http://www.choosingwisely.org/doctor-patient-lists/american-acad-
emy-of-neurology/Accessed August 22, 2013.
2. Fisher ES, Bynum JP, Skinner JS. Slowing the growth of health care
costs—lessons from regional variation. N Engl J Med 2009;360:
849–852.
3. Burke JF, Kerber KA, Iwashyna TJ, Morgenstern LB. Wide variation
and rising utilization of stroke magnetic resonance imaging: data
from 11 states. Ann Neurol 2012;71:179–185.
4. Burke JF, Gelb DJ, Quint DJ, et al. The impact of MRI on stroke
management and outcomes: a systematic review. J Eval Clin Pract
2013;19:987–993.
5. Haynes R, Sackett D. The architecture of diagnostic research. BMJ
2002;324:539–541.
DOI: 10.1002/ana.24034
Age, Rate of Change in Neuropathology, and Tra-
jectory of Cognitive Decline
Jagan A. Pillai, MBBS, PhD
Boyle et al present a striking analysis of cognitive decline among
856 subjects in relation to their neuropathology.1 They conclude
that 59% of late life cognitive decline was not explained by the
standard pathologic indices of the common causes of dementia.
Two related aspects of this analysis warrant comment.
First, the underlying assumption in their analysis is that
the amount of pathology contributes directly to trajectory of
cognitive decline. Another plausible relationship not discussed
is that the rate of buildup of neuropathology (not final neuro-
pathology burden at autopsy alone) could be related to rate of
cognitive decline.
Neuropathology builds up over the preceding decades
prior to onset of cognitive symptoms. Younger old individuals
in their sample (<75 years) could have an earlier start and/or
fewer number of years of pathology buildup before onset of
dementia with a faster rate of buildup of neuropathology than
the oldest old (>95 years).
Neuroimaging markers of cortical atrophy that relate to
cognitive decline have been noted to have a slower rate of
change with age among subjects >65 years old with Alzheimer
disease in the Alzheimer’s Disease Neuroimaging Initiative
study.2 Dementia rates have been reported to decrease with age
in some studies of subjects older than 90 years3 (but see Cor-
rada et al4). Even when the neuropathology burden is well char-
acterized, the rate of buildup in neuropathology and its
contribution to rate of cognitive decline could change with age.
Second, the study notes correlations between different
measures of neuropathology and age (the largest being 0.28),
but age at death did not change the core model significantly. It
is unclear from the results whether a linear model performs
adequately in capturing the trajectory of decline across age.
Results from the Medical Research Council Cognitive
Function and Ageing Study noted that the association between
neocortical neuritic plaques and dementia was strong at 75 years
of age and reduced at 95 years of age,5 but results from the Balti-
more Longitudinal Study of Aging did not note a similar relation-
ship.6 However, in the Gothenburg 951 study, strokes appeared
to show less association with dementia, mortality, and institution-
alization among 97-year-olds than reported in studies of younger
elderly populations. Given the interest and controversy regarding
the contribution of neuropathology burden to rate of cognitive
decline with age, it would be useful to know whether Boyle et al’s
conclusion applied equally to younger old persons and older old
persons in their large, well-characterized sample.
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